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ABSTRACT: Despite recent advances in structural definition of GPCR–G protein complexes, the basis of receptor
selectivitybetweenGproteins remainsunclear.TheGa12 andGa13 subtypes together form the least studiedgroupof
heterotrimeric G proteins. G protein–coupled receptor 35 (GPR35) has been suggested to couple efficiently to Ga13
but weakly to Ga12. Using combinations of cells genome-edited to not express G proteins and bioluminescence
resonance energy transfer–based sensors, we confirmedmarked selectivity of GPR35 for Ga13. Incorporating Ga12/
Ga13 chimeras and individual residue swapmutations into these sensors defined that selectivity betweenGa13 and
Ga12was imbued largelyby a single leucine-to-isoleucine variation at positionG.H5.23. Indeed, leucine couldnot be
substitutedbyother amino acids inGa13without almost complete loss ofGPR35 coupling. The critical importance of
leucine at G.H5.23 for GPR35–G protein interaction was further demonstrated by introduction of this leucine into
Gaq, resulting in the gain of coupling toGPR35. These studies demonstrate thatGa13 ismarkedly themost effective
G protein for interaction with GPR35 and that selection between Ga13 and Ga12 is dictated largely by a single
conservative aminoacidvariation.—Mackenzie,A.E.,Quon,T., Lin, L.-C.,Hauser,A.S., Jenkins, L., Inoue,A.,Tobin,
A. B., Gloriam, D. E., Hudson, B. D., Milligan, G. Receptor selectivity between the G proteins Ga12 and Ga13 is
defined by a single leucine-to-isoleucine variation. FASEB J. 33, 5005–5017 (2019). www.fasebj.org
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Recent years have seen enormous advances in knowledge
of the structural organization of members of the GPCR
superfamily (1–3), with many examples now available of
inactive state structures of rhodopsin-like, class AGPCRs.
Moreover, although less abundant, a significantnumberof
active state or active state–like structures have also been
described (4). A commondistinction between inactive and
active states is the reorientation of the intracellular facing
elements of the transmembrane helices, particularly of
transmembrane domain VI (5). It has long been appreci-
ated that the C-terminal a5 helix of G protein a subunits
engages with the active state receptor and that this is a
crucial step toward triggering guanine nucleotide ex-
change on the G protein a subunit to initiate steps that
result in regulation of signal transduction cascades (6, 7).
Although still limited in number (8–11), structural com-
plexes of an active state GPCR and a G protein have pro-
vided validation of suchmodels thatwere developed over
many years. Such a role of the extreme C-terminal region
of the G protein a subunit in engaging the agonist-
occupied receptor had been predicted. For example, the
site of pertussis toxin–catalyzed ADP-ribosylation, which
prevents effective interactions between GPCRs and Gai-
family G proteins, is the Cys residue located 4 aa from the
C-terminal tail in each of these Ga subunits (12), whereas
themolecular basis of the uncoupledmutation of Gas that
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also prevents interaction with appropriate GPCRs is a
single aminoacidalteration 6 residues from theC-terminal
tail (12). Moreover, the capacity to produce chimeric
G proteins that alter GPCR interaction selectivity by pro-
viding as few as the C-terminal 5–10 aa of a G protein a
subunit have been integral to such understanding (12).
Partially for convenience of classification, GPCRs are of-
ten designated as being coupled primarily to members of
one of the 4 families, Gas, Gai, Gaq/Ga11, and Ga12/Ga13,
of heterotrimeric G proteins. In many cases, this is well jus-
tified because the receptor in question clearly signals pre-
dominantly in a manner consistent with engagement with
members of only one of the 4 groups. However, in many
other cases studiesusing invitroexpression systems indicate
a broader G protein–coupling profile with, in certain ex-
amples, a degree of interaction with virtually all G proteins
tested (13). More importantly, a capacity to activate G
proteins from more than 1 G protein family is also true for
many receptors expressed natively, and this may dictate
distinct physiologic outcomes. For example, although free
fatty acid receptor 4 promotes secretion of the incretin
glucagon-like peptide 1 by activation of pertussis toxin–
insensitiveGproteinsof theGaq/11 family (14), regulationof
release of the satiety hormone ghrelin requires activation of
one or more pertussis toxin–sensitive Gai-family G protein
(15). Equally, although free fatty acid receptor 2 acts to
counter lipolysis in mouse white adipose tissue via a per-
tussis toxin–sensitivemechanism(16), effects of this receptor
on secretionof glucagon-like peptide 1 are insteadmediated
by Gaq/11-family G proteins (16). Although such examples
are clearly defined, there is often less understanding of the
importance of selective interactions of a receptor with dif-
ferent members from within one of the G protein families
and little insight into the molecular basis of such selectivity,
and there are currently no comparative structures of a single
GPCR in complex with 2 different G proteins.
Although clearly involved in GPCR-mediated cytoskel-
etal organization or reorganization and the consequences
thereof, the least studied of the Ga protein family is the 2-
member Ga12/Ga13 subgroup (17, 18). Although it is acti-
vated by many GPCRs, relatively little has been published
on these because of a lack of selective inhibitors, and assays
to measure their activation are challenging (19). However,
although Ga12 and Ga13 are generally coexpressed, mouse
knock-out studies demonstrate that they are not in-
terchangeable (17), and certain GPCRs appear to couple se-
lectively toGa12,Ga13, orboth.An interestingcase inpoint is
G protein–coupled receptor 35 (GPR35) (20). Although of-
ficially an orphan receptor, in that suggestions of its endog-
enous activator or activators remain controversial (20–24), a
wide range of surrogate agonists are available (20, 25). Al-
though coupling to Ga12/Ga13 is well established, the basis
ofpotential selectivity in sodoing isnot.Hereinweaddress2
key questions: Does GPR35 selectively activate Ga13 over
Ga12, and, if so,what is themolecularbasisof thisdifference?
MATERIALS AND METHODS
Materials for cell culture were fromMilliporeSigma (Burlington,
MA, USA) or Thermo Fisher Scientific (Waltham, MA, USA).
Polyethylenimine linear MW-25000 was from Polysciences
(Warrington, PA, USA). Zaprinast, lodoxamide, pamoic acid,
and a specific GPR35 antagonist (CID2745687) were purchased
from commercial sources. Compound 1 {4-[(Z)-[(2Z)-2-(2-
fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl]
benzoic acid} is described in Neetoo-Isseljee et al. (25). Bufrolin
[5,6-dimethyl-2-nitro-1H-indene-1,3(2H )-dione] is described in
Mackenzie et al. (26). 6-bromo-8-(4-methoxybenzamido)-4-
oxo-4H-chromene-2-carboxylic acid (PSB-13253) (27) was a
gift from Christa Muller and Dominik Thimm (University of
Bonn, Bonn,Germany). In all cases theGPR35a splice variant of
human GPR35 (hGPR35) was used.
Generation of bioluminescence resonance energy
transfer systematic protein affinity strength
modulation sensors
Systematic protein affinity strength modulation (SPASM) sen-
sors consisting of the receptor of interest [hGPR35a or mouse
GPR35 (mGPR35)]weregenerated based onpreviously reported
Fo¨rster resonance energy transfer SPASM sensors (28). These
sensors consist of a single construct of receptor, fused at its C
terminus to mCitrine, followed by an ER/K a helical linker (29),
the bioluminescent protein Nanoluc (Promega, Madison, WI,
USA), and to a peptide corresponding to the final 27 aa of Ga12,
Ga13, or Gaq. To ensure flexibility within the sensor unit, (Gly-
SerGly)4 linkers were included to separate each element—
mCitrine,ER/K linker,Nanoluc,Gpeptide—of the sensor. Sensors
were cloned using PCR and a seamless-end homology cloning
approach (ThermoFisher Scientific), generating constructs that did
not contain restriction enzyme sites separating the various sensor
elements. All constructs were fully sequenced prior to use.
Cell culture
Clones of cells genome-edited to lack expression of Gaq/Ga11,
Ga12/Ga13 or each of Gaq/Ga11/Ga12/Ga13 were derived from
parental human embryonic kidney 293 (HEK293) cells as pre-
viously described (30). Along with HEK293-T (T antigen) cells
and Flp-In T-REx 293 cells harboring various sensor constructs
these were grown in DMEM (MilliporeSigma) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, and 1%
penicillin/streptomycin. Cells were incubated in a humidified
CO2 incubator at 37°C.
Bioluminescence resonance energy transfer studies
using SPASM sensors
Flp-In T-REx 293 cell lines stably harboring the SPASM sensor of
interest were seeded into poly-D-lysine coated Greiner white 96-
well plates. Doxycycline (100 ng/ml) was added 3–4 h after
seeding to induce expression of the sensor, and cells were in-
cubated overnight at 37°C in 5% CO2. For transiently expressed
constructs,HEK293-T cellswere seeded toobtain 60%confluence
the following day. The cells were then transfected with 30 ng
DNA and 180 ng polyethylenimine per well 2 d prior to the
experiment. Thirty minutes before the assay, cells were washed
withHBSSbuffer containing 10mMHEPES and incubated in the
same buffer at 37°C. Because bioluminescence resonance energy
transfer (BRET) provides a ratiometric signal and herein the
constructs are single polypeptides, outcomes are anticipated to
be independent of expression levels.
Kinetic studies
Coelenterazine-h was added to each well to give a final concen-
tration of 5 mM 15 min prior to the read. Each well was read for
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30 s before addition of a ligand and read for a further 90 s before
any second addition. Wells were read throughout a 6-min win-
dow using a PheraStar plate reader (BMG Labtech, Cary, NC,
USA) for 0.5-s simulationswith filters forwavelengths of 475 nm
forNanoluc luminescenceand535nmformCitrineemission.The
rawvalue for 535nmwasdividedby the450-nmvalue toobtaina
BRET ratio. This value was then divided by the baseline value of
the first 30 s of read before the addition of any ligand to obtain a
fold change over baseline. This value for the vehicle-only addi-
tions for each cell type was subsequently subtracted from the
corresponding treatment to give the final value used for analysis.
Endpoint assay
Coelenterazine-h was added to each well to give a final concen-
tration of 2.5 mM 5 min prior to the addition of ligands. Wells
were read 5min after addition of ligands and hence 10 min after
addition of coelenterazine-h. Each well was read on a ClarioStar
plate reader for 0.5 s consecutivelyatwavelengths of 450645nm
for the Nanoluc luminescence and 550 6 45 nm for mCitrine
emission. The raw value for 550 nmwas divided by the 450 nm
value to obtain a BRET ratio. This value was subsequently di-
vided by the value of the vehicle-only addition to obtain a final
fold change over baseline value.
BRET studies using full-length G protein a subunits
The Nanoluc luciferase coding sequence was inserted in the hu-
manGa13 sequence immediately following residueArg128,with
(GlySerGly)4 linkers on either side. This position has previously
been verified as maintaining Ga13 function in Fo¨rster resonance
energy transfer studies that introduced a fluorophore at this lo-
cation (31). HEK293 cells genome-edited to lack expression of
both Ga12 and Ga13 were transiently transfected 2 d prior to the
experiment to coexpress hGPR35 tagged at the C terminus with
enhanced yellow fluorescent protein (eYFP) and the indicated
Nanoluc-containing Ga13 protein. BRET assays were conducted
as described above. Subsequent studies employed this base
Nanoluc-containing Ga13 construct in which residues G.H5.22
(Gln) and G.H5.23 (Leu) were altered to the corresponding resi-
dues of Ga12 (G.H5.22, Asp) or (G.H5.23, Ile).
b-Arrestin-2 interaction studies
These employed a BRET-based assay. HEK293-T cells were
transfected transiently to coexpress hGPR35-eYFPandb-arrestin-
2 taggedwithRenilla luciferase (32). Agonist-induced proximity
between these 2 proteins generated enhanced BRET signal upon
addition of the luciferase substrate coelenterazine-h.
High content imaging/internalization studies
These were performed essentially as described by Mackenzie
et al. (26). Briefly, Flp-In T-REx 293 cells harboring the hGPR35-
SPASMsensor of interestwere seeded into poly(D-lysine)–coated
black clear-bottom 96-well plates at a density of 80,000 cells per
well. Receptor expression was induced via the addition of
doxycycline (100 ng/ml) 6 h after seeding. Twenty-four hours
later, cells were washed twice with serum-free medium and in-
cubated with ligand for 45 min at 37°C, before being fixed with
paraformaldehyde (4% v/v). Cells were washed with PBS and
incubated with 10 mg/ml Hoechst nuclear stain at 37°C for
30 min to allow determination of cell number. Receptor in-
ternalization was quantified using an ArrayScan II high content
imager (Thermo Fisher Scientific), which detected the location of
the mCitrine fluorescent protein component of the sensor as it
was trafficked to endocytic recycling compartments.
TGF-a shedding assay
TGF-a shedding in response to activation of hGPR35 was
assessed as previously described (30, 33). Briefly, parental
HEK293 cells or cells of clones genome-edited to lack expression
of various G protein a subunit combinations (30, 34, 35) were
seeded onto 6-well plates (5 3 105 cells per well) 24 h prior to
transfection. Cells were transfected with 0.5 mg of a plasmid
containinganalkalinephosphatase (AP) fusionproteinofTGF-a,
AP-TGF-a, and 0.1 mg hGPR35. The next day, transfected cells
were trypsinized,washedwithHBSS, and reseededon to 96-well
plates 30 min prior to treatment with ligands. Cells were then
treated with agonists and incubated at 37°C for 1 h. After such
treatment, conditioned medium was transferred into other 96-
well plates. A solution of 10 mM paranitrophenylphosphate,
40 mM Tris-HCl (pH 9.5), 40 mMNaCl, and 10 mMMgCl2 was
added to both cell and conditioned medium plates, and the ab-
sorbance was measured at 405 nm before and after a 60-min
incubation at 25°C. TGF-a shedding was calculated as the per-
centage increase of optical density at 405 nm in conditioned
medium plate/overall total increase of optical density at 405 nm
(from both conditioned medium and cell plates).
Modeling studies
We first investigated sequence-based selectivity determinants in
Ga13 by evolutionary conservation forG.H5.23with its orthologs
and paralogs as previously described in Flock et al. (36).
Structure-based sequence alignments were performed using the
GPCR Database numbering for GPCRs and the Common Ga
Numbering scheme forGproteins (36, 37). In this scheme,G is the
G protein, H5 is the a5 helix, and the numerical value is the
position from the start of that helix (e.g., residue 23), hence
G.H5.23. Structural inspectionswereperformedon the receptor-G
protein complexes of b2-adrenoceptor-Gas (Protein Data Bank:
3SN6) and m-opioid receptor-Gai1 structure (Protein Data Bank:
6DDE). Structures were prepared using the protein preparation
wizard in Maestro (Schro¨dinger, New York, NY, USA) using de-
fault settings and including addition of missing residues followed
byH-bondassignment. InterfacecontactsbetweenG.H5.23andthe
receptor (including backbone interactions) were calculated using
Arpeggio using default settings (maximum range of interaction set
to 5.0 A˚) (38). Superpositioning, rotation calculations, and visuali-
zations were performed using PyMol (PyMol Molecular Graphics
System, v.2.0; Schro¨dinger).
RESULTS
hGPR35 can interact with G12/G13 but not
with Gq/G11
To assess the ability of hGPR35 to interact productively
withGproteins of the Ga12/Ga13 andGaq/Ga11 families,
we employed HEK293 cells, because they express all 4 of
these G proteins (30), and a TGF-a shedding assay (30, 33)
because it has previously been established that the TGF-
a shedding endpoint is promoted by receptors that
stimulate activation of any combination of Gq, G11, G12,
and G13 (30). Following transient cointroduction of
hGPR35 and an AP-tagged form of TGF-a (AP-TGF-a)
into parental HEK293 cells, the receptor was stimulated
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with either the most widely used GPR35 agonist zapri-
nast (39) (Fig. 1A) or the recently described high-potency
agonist lodoxamide (26) (Fig. 1B). These both promoted,
in a concentration-dependent manner, cleavage of AP-
TGF-a and its release from the surface of the cells. In
HEK293 cells that had been genome-edited using clus-
tered regularly interspaced short palindromic repeat
(CRISPR)–Cas9 (CRISPR-associated protein-9) (30, 34,
35) to eliminate expression of all 4 of Gaq, Ga11, Ga12,
and Ga13, shedding of AP-TGF-awas no longer evident
upon stimulation of hGPR35 (Fig. 1). Elimination of only
a combination of Ga12 and Ga13 from HEK293 cells also
prevented either of these hGPR35 active agonists from
promoting AP-TGF-a cleavage (Fig. 1). By contrast, in a
clone of HEK293 cells that had been genome-edited to
eliminate expression of only Gaq and Ga11 (34), the
2 phosphoinositidaseC–linkedGproteins that are expressed
by these cells, andwhich, therefore, still expressedGa12
and Ga13, both zaprinast and lodoxamide promoted
shedding of AP-TGF-a as effectively, and with equal
potency, as in the parental HEK293 cells (Fig. 1). In
combination with the lack of effect of activation of
hGPR35 in the Ga12/Ga13-null cells, this indicates that
hGPR35 does not interact productively with Gaq/
Ga11-family G proteins.
Development and characterization of
SPASM sensors
To provide improved quantification and to assess the rel-
ative degree of interaction of hGPR35with Ga12 and Ga13
we generated a pair of GPCR– G protein SPASM sensors.
In these theC-terminal tail of hGPR35was linked in-frame
to the C-terminal 27 aa of either G12 or G13a subunits via a
sequence that incorporated a BRET sensor that separates
the luciferase Nanoluc from the fluorescent protein mCi-
trinewitha 10nmflexible linker (Fig. 2A). Basedon similar
Fluorescence Resonance Energy Transfer–based SPASM
sensors for other GPCRs (28, 40) and structural insights
into themechanismsof interactionsbetweenGPCRsandG
proteins a subunits (7–12) we anticipated that following
construct expression agonist-induced engagement of the
G protein segment with the receptor would result in en-
hanced BRET signal. We cloned these sensors into Flp-In
T-REx 293 cells and, following doxycycline-induced
expression, studied initially the kinetics of response of the
Ga13-containing sensor upon addition of zaprinast. Zap-
rinast produced a rapid increase in BRET that was main-
tained over a period of at least 6min (Fig. 2B). CID2745687
has been described as a human ortholog specific antago-
nist of GPR35 (41, 42). Addition of CID2745687 after the
zaprinast-induced BRET signal had reached a steady,
maximal level rapidly reversed the effect of zaprinast at
hGPR35-Ga13 (Fig. 2B). It is well appreciated that rodent
orthologs of GPR35 display distinctly different ligand
pharmacology than hGPR35 (20), but whether rodent
forms of the receptor couple to the same G proteins as
hGPR35 isuncertain. Toassess this question,wegenerated
equivalent mGPR35-Ga12 and -Ga13 sensors. Following
similar stable expression in Flp-In T-REx 293 cells, zapri-
nast, which is also an effective agonist at mGPR35 (20),
once again produced a large BRET signal at the Ga13-
sensor that was maintained over time (Fig. 2C). Addition
of CID2745687, however, failed to reverse the effect of
zaprinast at mGPR35-Ga13 (Fig. 2C). This is consistent
with previous in vitro studies showing that CID2745687 is
a high-affinity antagonist at hGPR35 but has little affinity
for mGPR35 (42). This suggests that reported effects of
CID2745687 in cells and tissues from rodents (43, 44)
probably reflect off-target effects of the compound rather
than being mediated by GPR35.
A wide range of previously characterized ligands with
agonism at hGPR35, including zaprinast (39) (Fig. 3Ai),
pamoic acid (41) (Fig. 3Aii), lodoxamide (26) (Fig. 3Aiii),
PSB-13253 (27) (Fig. 3Aiv), compound1 (25) (Fig. 3Av), and
bufrolin (26) (Fig. 3Avi), added tocells expressinghGPR35-
Ga13 all produced robust and concentration-dependent
increases in BRET signal. This was also the case for
hGPR35-Ga12 (Fig. 3A). Although the measured EC50 of
each of the agonists tested was very similar for activation
of Ga12 and Ga13 (Table 1), in every case the maximal
response of the Ga13-based sensor was markedly higher
(Fig. 3A). To demonstrate the critical role of the G protein
C-terminal sequence in promoting the observed increase
in BRET signal, we also generated a control no-peptide
(NP) hGPR35-SPASM construct that simply lacked such a
C-terminal sequence. Following its stable expression and
induction in Flp-In T-REx 293 cells, none of the agonists
was able to enhance the basal BRET signal of the NP
sensor (Fig. 3A). In further support of the ability of these
hGPR35-SPASM sensors to report the pharmacological
Figure 1. hGPR35 promotes shedding of an AP-
tagged form of TGF-a via activation of G12/13
but not via Gq/G11. The ability of varying
concentrations of either zaprinast (A) or
lodoxamide (B) to promote shedding of an
AP-tagged form of TGF-a was assessed follow-
ing cotransfection of hGPR35 and AP-TGF-a
into each of parental HEK293 cells (circles) or
clones of HEK293 cells that had been genome-
edited to lack expression of Ga12 + Ga13
(diamonds), Gaq + Ga11 (squares), or a combi-
nation of Gaq, Ga11, Ga12, and Ga13 (triangles).
Basal levels of AP-TGF-a release were subtracted.
Data represent means 6 SD in triplicates from
each group of a single experiment representative
of 3 performed.
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characteristics of GPR35 agonists appropriately, as il-
lustrated in Fig. 3Bi, ii, pamoic acid, although potent,
clearly acted as a partial agonist comparedwith the other
ligands at both the Ga13- and Ga12-containing sensors.
This is fully consistent with findings using other assay
endpoints, including binding of [35S]GTPgS and receptor
Figure 2. Kinetics of activation and deactivation
of GPR35-Ga sensors. A) A diagram illustrates
the nature of the GPR35–G protein sensors
used and why G protein engagement induced
by binding of an agonist ligand to the receptor
is anticipated to result in enhanced BRET
signal as the Nanoluc (NLUC) and mCitrine
(mCit) components move closer together. B,
C) Flp-In T-REx 293 cells stably harboring
hGPR35-Ga13 (B) or mGPR35-Ga13 (C) were
treated with doxycycline to induce construct
expression. Kinetic studies were then per-
formed to assess changes in BRET signal over
time. Zaprinast (red) (EC80 16 mM for human
and 1 mM for mouse) or vehicle (blue) (HBSS
with DMSO) were added at time 30 s (first
vertical line) and maintained for a further
330 s. In certain studies, the human-specific
GPR35 antagonist CID2745687 (CID) (green)
(10 mM) was added at 120 s (second vertical
line).
Figure 3. Validation and demonstration of effectiveness of hGPR35-Ga12 and hGPR35-Ga13 SPASM sensors. A) Flp-In T-REx 293
cells stably harboring hGPR35-Ga13 (squares), hGPR35-Ga12 (triangles), or hGPR35-NP (circles) were treated with doxycycline
to induce construct expression; such cells were then treated with varying concentrations of zaprinast (i), pamoic acid (ii),
lodoxamide (iii), PSB-13253 (PSB) (iv), compound 1 (v), or bufrolin (vi) for 5 min, and alteration in BRET signal was compared
with basal. B) Data from A for the 4 denoted agonists are replotted, with maximal response to zaprinast defined as 100%. For
both hGPR35-Ga13 (i) and hGPR35-Ga12 (ii), pamoic acid acted as a partial agonist compared with the other ligands. C) The
same ligands as shown in B were used to assess interactions between hGPR35 and b-arrestin-2 in a BRET-based assay following
transient cotransfection of hGPR35-eYFP and b-arrestin-2–Renilla luciferase into HEK293T cells. D) Correlation of potency of all 6
ligands shown in A in assays using the hGPR35-Ga13 sensor and the hGPR35a–b-arrestin-2 interaction assay is shown. E, F)
Although the construction of the SPASM sensors adds a substantial molecular construct to the C-terminal tail of hGPR35, it does
not prevent effective agonist-induced internalization of the constructs from the surface of Flp-In T-REx 293 cells expressing such
constructs: hGPR35-Ga13 (E), hGPR35-NP (F).
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internalization (32). Of equal importance in further val-
idating use of the SPASM sensors, the potency measures
for activation of the Ga13-containing sensor by different
agonists were highly correlated (r2 = 0.98) with values
obtained in BRET-based hGPR35–b-arrestin-2 interaction
assays (Fig. 3C, D) that have provided the most widely
used approach to identify and characterize ligands at
GPR35 (25, 26, 41, 42). Interaction with a b-arrestin is an
important step in agonist-induced internalization of
many GPCRs (34) including GPR35. The G protein–
containing sensor constructs retained the capacity to be
internalized from the surface of their host Flp-In T-REx
293 cells upon exposure to either the high-potency ago-
nist lodoxamide or the lower-potency agonist zaprinast,
as assessed using a high-content imaging platform that
detects the intracellular location of the mCitrine fluo-
rescent protein component of the sensors (Fig. 3E), and
this was also the case for the equivalent hGPR35-NP
sensor (Fig. 3F).
The molecular basis for selective coupling
to Ga13
The marked difference in effectiveness of agonists at the
hGPR35-Ga13 sensor and the hGPR35-Ga12 sensor, cou-
pled with earlier evidence that hGPR35 selectively inter-
acts with Ga13 over Ga12 (32), led us to assess the
molecularbasis for this difference. Studieswith chimericG
protein a subunits have shown that substitution of be-
tween 5 and 10 aa at the extreme C-terminal end of a G
protein, which is within the a5 helix, is sufficient to switch
GPCRselectivity (12).Within this region thereareonly4aa
differences between Ga13 and Ga12 (Fig. 4A, B). These
differences are a pair of residues located at positions210
[Common Ga Numbering system (35, 36) G.H5.17] and
29 (G.H5.18) and a pair of amino acids at positions25
(G.H5.22) and 24 (G.H5.23) (Fig. 4B). Initially we swap-
ped His and Asp at positions G.H5.17 (His) and G.H5.18
(Asp) of Ga13 for the equivalent amino acids, Gln andGlu,
in Ga12 and vice versa in the context of the hGPR35 sensors.
This had little effect on function compared with the wild
type sequences (Fig. 4C), and this was the case for all
hGPR35 agonists that we assessed (Fig. 4C). However,
when we exchanged the residues Asp and Ile at positions
G.H5.22 (Asp) and G.H5.23 (Ile) of Ga12 into Ga13 to re-
place Gln and Leu, activation by agonists resulted in as
limited BRET signal as with full-length Ga12 (Fig. 4D). The
oppositewas truewhenGln andLeu fromGa13were used
to replaceAsp and Ile in theGa12 sequence. This generated
a sensor with substantial gain of function that was now
almost equivalent to the full sequence fromGa13 (Fig. 4D).
Once again, this was the case nomatterwhether zaprinast,
lodoxamide, pamoic acid, or bufrolinwas employed as the
agonist (Fig. 4D).
We extended these studies by replacing only a single
residue at a time. Remarkably, given the physiochemical
similarities of Leuand Ile, substitutionofLeu (G.H5.23) for
Ile in Ga12 generated an hGPR35-SPASM sensor that
responded almost as well to GPR35 agonists as the full
sequence from Ga13 (Fig. 5A). By contrast, substitution of
Asp (G.H5.22) by Gln in Ga12, although it produced an
enhanced response to each of zaprinast, lodoxamide,
pamoic acid, and bufrolin compared with the wild type
Ga12 sequence (Fig. 5A), resulted in a much more limited
effect compared with the introduction of Leu (G.H5.23) in
place of Ile. Finally, in this context we assessed whether
LeuatpositionG.H5.23was theonlyaminoacid thatcould
provide effective coupling between hGPR35 and a Ga13-
based G protein. This was the case; alteration of this resi-
due to any of Val, Ala, Met, Cys, Tyr, or Phe generated a
sensor that was not activated more effectively than either
G.H5.23 Ile Ga13 or full-length Ga12 (Fig. 5B), and once
more this was true when assessing a range of chemically
distinct GPR35 agonist ligands (Fig. 5B). These amino
acids were selected because they cover the identity of
residue G.H5.23 across mammalian G protein a subunits.
Although BRET provides a ratiometric signal that is an-
ticipated to be independent of construct expression level,
wedirectly examined the relative expression levels of each
of the G.H5.23 point mutant forms of the Ga13- and Ga12-
containing GPR35 sensors used in these transient expres-
sion experiments by directly measuring luciferase activity
(Fig. 5B). This examination showed that the Ga12 sensor
construct was expressed at a very similar level as the Ga13
sensor construct, although it generated a very limited
signal compared with the Ga13 sensor, and that alteration
of residue G.H5.23 in the Ga13 sensor across the range of
amino acids introduced had no substantial effect on con-
struct expression levels. The GPR35-NP sensor was
expressed at rather higher levels than the others, and this
may indicate that the G protein segment of the other
constructs reduces expression.
This selectivity is maintained in
full-length Ga13
To ensure that outputs from the SPASM sensor stud-
ies would correlate with effects observed with the
TABLE 1. Potency of ligands at hGPR35-Ga12 and hGPR35-Ga13 sensors
Ligand hGPR35-Ga12 pEC50 6 SEM hGPR35-Ga13 pEC50 6 SEM
Zaprinast 5.22 6 0.10 5.20 6 0.07
Pamoic acid 7.40 6 0.15 7.44 6 0.09
Lodoxamide 8.08 6 0.09 8.22 6 0.06
PSB-13253 7.49 6 0.10 7.63 6 0.04
Compound 1 7.33 6 0.09 7.16 6 0.08
Bufrolin 7.59 6 0.11 7.89 6 0.10
Data represent the mean 6 SEM from at least 3 independent experiments; p, negative logarithm.
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corresponding full-length G proteins, Ga13 was next
modified by insertion ofNanoluc at residue position 128.
This construct was cotransfected with hGPR35-eYFP
intoHEK293 cells lacking bothGa12 andGa13, and BRET
was measured as a surrogate of receptor-G protein in-
teraction following addition of varying concentrations of
zaprinast (Fig. 6A) or lodoxamide (Fig. 6B). Subsequent
studies employed this base G protein construct with
residues G.H5.22 (Gln), G.H5.23 (Leu), or both altered to
the corresponding residues of Ga12 (G.H5.22, Asp) or
(G.H5.23, Ile) (Fig. 6). The results using these variants
were very similar to those obtainedusing the equivalent
Figure 4. G12/G13 selectivity for hGPR35 resides
within the C-terminal 10 aa. A) The C-terminal
27 aa of Ga12 and Ga13 are shown with amino
acids that differ within the last 10 aa boxed. B)
The Common Ga Numbering system (36, 37) is
used to highlight these differences and their
positions within the C-terminal G protein a5
helix. C, D) hGPR35-SPASM sensors were
constructed in which residues at positions
G.H5.17 and G.H5.18 (C) or G.H5.22 and
G.H5.23 (D) were swapped between Ga12 and
Ga13. Following stable expression and induc-
tion in Flp-In T-REx 293 cells, the ability of
each of zaprinast (i), lodoxamide (ii), pamoic
acid (iii), and bufrolin (iv) to enhance BRET
signals was compared with the effect of these
ligands at the hGPR35-Ga13, hGPR35-Ga12,
and hGPR35-NP sensors.
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SPASM sensors. The largest signal was achieved using
wild type full-length Ga13 (Fig. 6). Replacement of
G.H5.22 (Gln) by Asp reduced interactions between re-
ceptor and G protein to a small extent, whereas re-
placement of G.H5.23 (Leu) by Ile or a combination of
replacement of G.H5.22 (Gln) and G.H5.23 (Leu) by Asp
and Ile resulted in forms of full-length Ga13 that were
unable to interact effectively with GPR35 in an agonist-
dependent manner (Fig. 6). This was the case when either
zaprinast (Fig. 6A) or lodoxamide (Fig. 6B) was used as
agonist.
Computational analysis
The G.H5.23 position is not conserved among the human
Ga subtypeparalogs (7Ga subtypeswithCys, 2with Ile, 4
with Tyr, 1 with Phe, and 1 with Leu) but is highly con-
servedamong theGa12 andGa13 orthologs. This renders it
part of the selectivity-determining G protein barcode (36)
(Fig. 7A). Residue positions in this barcode represent the
determinants of GPCR–G protein selectivity, as deduced
from evolutionary conservation (conserved in orthologs
but not in paralogs) (36). Given the limited structural
coverage of receptors and complexes to model a GPR35-
Ga13 complex, we looked at the currently available
receptor–G protein complexes of m-opioid receptor–Gai1
(45), b2-adrenoceptor–Gas (8), adenosine A1 receptor–
Gai2 (46), and 5-HT1A–Gao1 (47) to attempt to rationalize
the importance of G.H5.23 for G13 function. A comparison
between these structures revealsdifferences in theposition
of transmembrane receptor helix VI and in the orientation
between the G protein’s a5 helix domain (;20° rotation)
(Fig. 7B). For the b2-adrenoceptor–Gas complex, G.H5.23
(Tyr) has hydrophobic contacts with positions 2339,
3349, 3350, and 3353 of the receptor, whereas G.H5.23
(Cys) contacts 2339, 3349, 3350, 34357 (intracellular
loop2), and8347 in them-opioid–Gai1; 3350, 3354, 6336,
Figure 5. G12/G13 selectivity for hGPR35 is
defined predominantly by a single leucine/
isoleucine variation. A) In experiments akin to
Fig. 4, hGPR35-G protein sensors were con-
structed and expressed in which single amino
acids at positions G.H5.22 and G.H5.23 were
swapped between Ga12 and Ga13, and the
effect of the denoted ligands [zaprinast (i),
lodoxamide (ii), pamoic acid (iii), and bufrolin
(iv)] were compared with results generated
using the hGPR35-Ga13, hGPR35-Ga12, and
hGPR35-NP sensors. B) Position G.H5.23 (Leu)
in Ga13 was altered to a number of other amino
acids, and functionality was assessed in response
to the noted GPR35 agonists [zaprinast (i),
lodoxamide (ii), and pamoic acid (iii)], with
parallel responses of hGPR35-Ga13, hGPR35-
Ga12, and hGPR35-NP sensors recorded as
controls. Direct measures of luciferase activity in
cells transiently expressing these constructs de-
fined their relative expression levels (iv).
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6340, and 7353 in 5-HT1B–Gao; and 3350, 3353, 7353,
and 8347 in adenosine A1–Gai2 (Fig. 7C). The distinct
binding patterns of the available structures suggest there
must be a further distinct binding mode for GPR35-Ga13.
Thus, it is plausible that this specific binding pose is highly
constrained in space and hence only Leu has the correct
balance of hydrophobicity, flexibility, isotropic surface
area, and electrostatic properties.
Introduction of G.H5.23 Leu into Gaq allows
coupling to GPR35
It is intriguing, therefore, that although a GPR35-Gaq
SPASM sensor was not activated by GPR35 agonists (Fig.
8A), replacement of G.H5.23 (Tyr in Gaq) by Leu also
generated a sensor for GPR35 that provided a substantial
level of functionality (Fig. 8A). To also extend this to the
context of full-lengthGproteina subunits,we generated a
Tyr-Leu mutation at G.H5.23 in Gaq and introduced this
variant, along with hGPR35, into HEK293 cells genome-
edited to lack each of Gaq, Ga11, Ga12, and Ga13. Now, in
TGF-a shedding studies, both zaprinast and lodoxamide
wereable topromote releaseofAP-TGF-a ina concentration-
dependent manner (Fig. 8B) and with potency for the 2
agonists that was not significantly different from that
observed in either parental HEK293 or Gaq plus Ga11
knock-out HEK293 cells (Fig. 1). Moreover, the effective-
ness of TGF-a shedding induced by either of these GPR35
agonists when activating G.H5.23 Leu Gaq was equiva-
lent to that observedwhenwe instead introduced into the
genome-edited cells lacking each of Gaq, Ga11, Ga12, and
Ga13 a chimeric form of Gaq/Ga13 in which all of the
C-terminal 6 aa were derived from Ga13 (Fig. 8B).
DISCUSSION
Although many GPCRs display a level of promiscuity in
coupling to several families of heterotrimeric G proteins,
there is little known about potential receptor selectivity
between more closely related members of each of the 4
broad, generic families. Detailed studies on theGs, Gi, and
Gq families reflect their direct roles in the regulation of
levels of secondary messengers and that toxins and
chemical tools that disrupt signaling viamembers of these
families are available and are used widely (12, 48). By
contrast, theG12/G13group ismuch less studied, although
these play central roles in cytoskeletal organization and
signaling viaRho-family small monomeric G proteins. It is
also clear thatmanyGPCRs can anddo cause activation of
these G proteins, but direct, easy-to-measure assays of
their stimulation are not broadly available. CertainGPCRs
do, however, appear to display considerable selectivity for
G12/G13 over other G proteins, and in the case of the
nominally orphan receptor GPR35 it has been suggested
that there is even marked selectivity for G13 over G12 (49).
To assess this in a controlled and potentially quantitative
manner, we established a range of SPASM sensors (28, 40)
in which hGPR35a was linked to the C-terminal 27 aa of
various G protein a subunits via a flexible linker in which
receptor interaction with the G protein segment results in
enhanced BRET signal. A variant NP form, lacking the G
protein segment, did not result in altered BRET with ad-
dition of various agonists at hGPR35, demonstrating that
the G protein segment was indeed required for signal al-
teration. Moreover, in agreement with studies conducted
using a TGF-a shedding assay performed in cells from
which various G proteina subunits had been removed via
genome editing, an hGPR35-Gaq SPASM sensor did not
respond to GPR35 agonist ligands.
A number of key outcomeswere produced. First, using
a sensor containing hGPR35 and the C-terminal 27 aa of
Ga13, a large increase in BRET signal was generated fol-
lowing the addition of a range of chemically distinct ago-
nists. This sensor provided an appropriate measure of
ligand potency because the potency profile in this assay
was highly correlated with outcomes from an hGPR35–b-
arrestin-2 interaction assay that has been widely used to
identify novel agonists at this receptor (26, 27, 41, 42).
Moreover, it also provided a suitable estimate of agonist
efficacybecausepamoic acid clearly functionedas apartial
agonist, as previously defined in a range of other assays.A
further key observation that validated the use of the sen-
sors was that although a sensor containing mGPR35 was
also activated effectively by zaprinast, which has similar
potency atmGPR35 andhGPR35 (20), CID2745687,which
is a human-specific antagonist of GPR35 (20, 42), was
unable to reverse the effect of zaprinast at the mGPR35-
containing sensor. It is important to highlight that al-
though hGPR35 and mGPR35 are poorly conserved
overall in their sequences, they do engage effectively with
the same G protein in Ga13. Secondly, although the ago-
nists tested are able to also activate Ga12 in such a sensor
Figure 6. The importance of residue G.H5.23 in
Ga13 sensors is maintained in the full-length
G protein sequence. hGPR35-eYFP was coex-
pressed in HEK293 cells with forms of full-
length Ga13 that either were wild type, had
residue G.H5.22 converted to Asp, had residue
G.H5.23 converted to Ile, or contained both of
these alterations. Nanoluc had been intro-
duced into all of the forms of Ga13 to provide
a potential BRET pairing with the eYFP-tagged
receptor. Cells were then stimulated with
varying concentrations of either zaprinast (A)
or lodoxamide (B). Data are shown as means 6
SD (n = 3).
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construct, the maximal signal of all GPR35 agonists tested
was substantially lower than for Ga13. Because this assay
generates a ratiometric signal, variations in response
would not be anticipated to be related to expression level.
Moreover, direct measures of the fluorescence of the
mCitrine component of the BRET sensor indicated very
similar expression levels of hGPR35-Ga13 and hGPR35-
Ga12. As such, these outcomes indicated either that
Figure 7. Modeling studies. A) Snake-like diagram of Ga13 with the G protein barcode highlighting evolutionary neutral,
conserved, and selectivity-determining positions (barcode cutoff 0.96). B) Location of G.H5.23 (cyan) in the receptor-G protein
complex (left) and comparison of the a5 helix domain C termini of Gas (green) and Gai1 (red) (right). Arrows indicate the
rotation differences between the a5 helix domains. Comparison of interface contacts and contacting residues between recently
published GPCR–G protein structures are shown, as well as for the GPR35 G12/G13 selectivity-determining position G.H5.23. C)
Alignment of G.H5.23 contacting receptor residue positions (gray: conserved; yellow: differing). This suggests a structurally yet-
to-be-defined, alternative binding mode and contact profile for the G12/G13 family subtypes and their receptor coupling partners.
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hGPR35 interacts substantially less effectively with Ga12
thanwithGa13 or thatmarkedvariations in theorientation
of these interactions alter the proximity of the Nanoluc-
mCitrine BRET pair within the sensor. Although it is im-
possible to separate these possibilities conclusively, the
fact that alteration of a single amino acid (G.H5.23) be-
tween Leu and Ile produced signal-level switches close to
those observed for the full sequences of Ga13 and Ga12
strongly favors the effect as being an intrinsic difference in
interaction of the receptor between the 2 proteins. More-
over, replacement of Leu at position G.H5.23 in the se-
quence of Ga13 with any amino acidwe tried resulted in a
loss of agonist-induced BRET to a level at or below those
obtained with the Ga12 sequence. A sensor containing the
C-terminal 27 aa of Gaq/Ga11 (these 2 G proteins are
identical over this region) showed no agonist-induced
signal, but, remarkably, simple replacement of Tyr
G.H5.23 by Leugenerateda substantial level of interaction,
and this was also observed in the TGF-a shedding assay
whenwe introduced Leu in place of Tyr in full-length Gaq.
Although GPCR and cognate G protein structure de-
termination is advancing rapidly (8, 45–47), there are little
direct data on howmuch differencemight be expected for
a receptor in complexwith 2 different G proteins. Van Eps
et al. (50) have suggesteddifferences in theways inwhich2
distinct GPCRs interact with their cognate G proteins, but
the outcomes are predictions rather than direct compari-
sons. Kleinau et al. (51) have taken a mutagenic approach
toaddress selective interactionsof the thyrotropin receptor
with Gs and with Gq, but these studies focused on the
receptor rather than the G protein. A study with a larger
direct relevanceused the SPASMapproach also employed
herein to assess differences in interactions between re-
ceptors with Gas and Gaq, 2 still markedly different G
proteins from different families (40). Furthermore, an ex-
tensive computational analysis on the potential basis for
GPCR–G protein selectivity by Flock et al. (36) explored a
potential barcode for receptor selectivitywithin the amino
acid sequences at the C-terminal region of different G
proteins. However, this remains challenging to interpret
fully in the absence of a broader range of atomic-level
structures and provided no insights into potential selec-
tivity between Ga13 and Ga12, perhaps in part because
these are the G proteins for which the most limited GPCR
interaction profiles have been reported.
We have also taken advantage of the most recent data
on natural genetic variations in the human population
from the Genome Aggregation Database, consisting of
123,136 exome sequences (52). Strikingly, no natural mu-
tations havebeenobserved in any individual atG.H5.23 in
Ga12 or Ga13, which suggests that G.H5.23 in G12/G13 is
under strong selection in the human population. In-
terestingly, a Ga13 G.H5.23 Leu374-Ile mutation and a
Ga12 G.H5.23 Ile378-Ser mutation have been reported in
the Catalogue of Somatic Mutations in Cancer (53). In the
case of the Ga13 G.H5.23 Leu374-Ile mutation, our study
suggests this is linked to reduced function in response to
GPR35activation, and itwill be interesting toexplore if this
is also the case for otherGa13-interacting receptors.GPR35
has been reported to be up-regulated in breast cancer tis-
sue compared with normal adjacent tissue (54), but the
overall significance of this remains uncertain.
Taken together, Ga13 Leu374 (G.H5.23) seems to be the
single most relevant residue for G protein selectivity, at
least for GPR35. However, the molecular details of this
phenomenon are yet to be elucidated in structural and
mutational studies (on the receptor side) to pinpoint the
G12/G13 specific receptor interfacepartners ofG.H5.23.
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